Kazia Therapeutics (ASX:KZA) Current Accrued Expense : A$4.95 Mil (As of Dec. 2023)

View and export this data going back to 1994. Start your Free Trial

What is Kazia Therapeutics Current Accrued Expense?

Kazia Therapeutics's Current Accrued Expense for the quarter that ended in Dec. 2023 was A$4.95 Mil.

Kazia Therapeutics's quarterly Current Accrued Expense increased from Dec. 2022 (A$0.84 Mil) to Jun. 2023 (A$3.47 Mil) and increased from Jun. 2023 (A$3.47 Mil) to Dec. 2023 (A$4.95 Mil).

Kazia Therapeutics's annual Current Accrued Expense increased from Jun. 2021 (A$0.00 Mil) to Jun. 2022 (A$2.24 Mil) and increased from Jun. 2022 (A$2.24 Mil) to Jun. 2023 (A$3.47 Mil).

Kazia Therapeutics Current Accrued Expense Historical Data

The historical data trend for Kazia Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kazia Therapeutics Current Accrued Expense Chart

Kazia Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Current Accrued Expense

Get a 7-Day Free Trial

0.71

1.80

2.24

3.47

Kazia Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Current Accrued Expense	Get a 7-Day Free Trial															4.19	2.24	0.84	3.47	4.95

Kazia Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Kazia Therapeutics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Kazia Therapeutics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Kazia Therapeutics (ASX:KZA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kazia Therapeutics Ltd (ASX:KZA) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

KZIA:USA

Address

300 Barangaroo Avenue, Level 24, Three International Towers, Sydney, NSW, AUS, 2000

Website

https://www.kaziatherapeutics.com

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.

Kazia Therapeutics (ASX:KZA) Headlines

No Headlines